AGAP2 and breast carcinoma: Recent evidence shows that AGAP2‐AS1 could epigenetically regulate MyD88 expression to promote chemoresistance in patients with breast cancer.15 In addition, Li et al16 reported that the elevated expression of AGAP2‐AS1 regulates downstream target transcription in non–small‐cell lung cancer by interacting with epigenetic proteins.